NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S....